share_log

Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $34

Benzinga ·  Jul 23 12:55  · Ratings

Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $30 to $34.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment